2701 EASTLAKE AVE EAST, SEATTLE, WA
Nautilus Biotechnology Enters $125 Million Sales Agreement with TD Cowen
Financial Results, Press Release
Nautilus Biotechnology Elects Class II Directors at Annual Meeting
Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Other Events
Reports Third Quarter 2025 Financial Results
Q2
Q1
FY 2024
Q3
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement